ArticleEuropean journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V2011
Relationship between the size of nanoparticles and their adjuvant activity: data from a study with an improved experimental design.
Article in European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Silver nanoparticles synthesised using endophytic fungus Calonectria eucalypti from medicinal plant axifraga stolonifera and their bioactivity.Journal, genetic engineering & biotechnology · 2025Article
- Article
- The Elicitation of an Antigen-Specific Antibody Immune Response Using a Nanoparticulate Adjuvant Derived fromMolecules (Basel, Switzerland) · 2025Article
- Article
- Duration of the antibody response following intradermal administration of a quarter-dose oil adjuvant foot-and-mouth disease vaccine in sheep.Veterinary research communications · 2025Article
- Emerging Cationic Nanovaccines.Pharmaceutics · 2024Review
- Precision Nanovaccines for Potent Vaccination.JACS Au · 2024Review
- Virus-like Particle (VLP) Vaccines for Cancer Immunotherapy.International journal of molecular sciences · 2023Review
- Nanoadjuvants: Promising Bioinspired and Biomimetic Approaches in Vaccine Innovation.ACS omega · 2023Review
- Non-canonical inflammasome activation mediates the adjuvanticity of nanoparticles.Cell reports. Medicine · 2023Article
- Machine Learning-Assisted Screening of Herbal Medicine Extracts as Vaccine Adjuvants.Frontiers in immunology · 2022Article
- Development of Lipidoid Nanoparticles for siRNA Delivery to Neural Cells.The AAPS journal · 2021Article
- Using PAMPs and DAMPs as adjuvants in cancer vaccines.Human vaccines & immunotherapeutics · 2021Review
- Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges.Nature reviews. Clinical oncology · 2020Review
- Advantages and Prospects of Tag/Catcher Mediated Antigen Display on Capsid-Like Particle-Based Vaccines.Viruses · 2020Review
- Development of Different Methods for PreparingFrontiers in immunology · 2020Article
- Modulation of Immune Responses by Particle Size and Shape.Frontiers in immunology · 2020Review
- Critical Size Limit of Biodegradable Nanoparticles for Enhanced Lymph Node Trafficking and Paracortex Penetration.Nano research · 2019Article
- Optimal therapeutic strategy using antigen-containing liposomes selectively delivered to antigen-presenting cells.Cancer science · 2019Article
- Reprogramming the adjuvant properties of aluminum oxyhydroxide with nanoparticle technology.NPJ vaccines · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
There is a growing interest in identifying the relationship between the size of nanoparticles and their adjuvant activity, but the results from recent studies remain controversial. To address the controversy, it was thought that one should pay attention to the nanoparticle formulations to make sure that the antigen-loaded nanoparticles to be compared are not only different in particle size, but more importantly, as identical to each other as possible in all other formulation properties. In the present study, using ovalbumin (OVA) as a model antigen conjugated onto nanoparticles engineered from lecithin/glyceryl monostearate-in-water emulsions, we prepared OVA-nanoparticles of 230 nm and 708 nm. Before evaluating the immune responses induced by them in a mouse model, we made sure that: (i) the sizes of the two OVA-nanoparticles did not extensively overlap, (ii) the nanoparticles have similar zeta potentials and comparable antigen-loading, and (iii) the nanoparticles did not aggregate when suspended in simulated biological media. We then showed that when subcutaneously injected into mice, the 230 nm OVA-conjugated nanoparticles induced stronger OVA-specific antibody and cellular immune responses than the 708 nm OVA-nanoparticles. Future studies attempting to correlate the size of nanoparticles and their adjuvant activities need to consider formulation parameters to ensure that the particles are different only in size and are stable before and after injection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.